Somatostatin analogues and PRRT treatment for metastatic paraganglioma
Endocrinology, Diabetes & Metabolism Case Reports · 01.10.2026 · 2026 (4)
DOI: 10.1530/edm-25-0150 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrinology, Diabetes & Metabolism Case Reports, erschienen am 01.10.2026. Verfasst von Catarina Regala und 3 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology, Diabetes and Metabolism Department, Instituto Português de Oncologia de Lisboa Francisco Gentil , Lisbon, Portugal. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Summary Phaeochromocytomas and paragangliomas are rare neuroendocrine tumours arising from the adrenal medulla and extra-adrenal paraganglia, respectively, with symptoms driven by catecholamine excess or tumour mass effect. At least 40% of these are related to germinal mutations, and metastatic disease is present in around 25% of patients, more frequently associated with SDHB mutations. Current therapeutic options beyond timed surgery have modest results, and new alternatives are needed. We report a case of a 45-year-old woman presenting with thoracic pain and upper limb paraesthesia. Thoracic CT imaging revealed a 6-cm right apical thoracic lesion extending into D1–D2 vertebrae, and laboratory tests revealed markedly elevated urinary normetanephrines. Following a subtotal resection and 131I-MIBG therapy, the patient was lost to follow-up for four years before returning with local recurrence and lymphatic and bone metastases. A second surgery and adjuvant stereotactic radiotherapy resulted in stable disease for 16 months. Upon further disease progression, with multiple new bone lesions showing strong somatostatin receptor expression on 68Ga-DOTANOC PET, lanreotide was initiated, resulting in 17 months of stable disease. Subsequent disease progression with hepatic and suspected pancreatic metastases was treated with four cycles of 177Lu-DOTATATE peptide receptor radionuclide therapy, achieving sustained stable disease on follow-up imaging at six and 16 months. This case highlights the potential value of sequential somatostatin analogue and PRRT for metastatic PPGLs, providing meaningful and durable disease control in the absence of curative options, while emphasizing the need for randomized studies to validate and define the role of these emerging therapies. Learning points
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Endocrinology, Diabetes and Metabolism Department, Instituto Português de Oncologia de Lisboa Francisco Gentil , Lisbon, Portugal.
- Endocrinology, Diabetes and Metabolism Department, Hospital Garcia de Orta , Almada, Portugal.
- Unidade Investigação Patobiologia Molecular (UIPM), Instituto Português de Oncologia de Lisboa Francisco Gentil , Lisbon, Portugal.
ORCID-Profile: Catarina Regala, João Roque, Tiago Nunes da Silva
Zitieren
APA
Regala, C., Roque, J., Leite, V., & Nunes da Silva, T. (2026). Somatostatin analogues and PRRT treatment for metastatic paraganglioma. Endocrinology, Diabetes & Metabolism Case Reports, 2026(4). https://doi.org/10.1530/edm-25-0150
Vancouver
Regala C, Roque J, Leite V, Nunes da Silva T. Somatostatin analogues and PRRT treatment for metastatic paraganglioma. Endocrinology, Diabetes & Metabolism Case Reports. 2026;2026(4). doi:10.1530/edm-25-0150
BibTeX
@article{Regala2026,
author = {Regala, Catarina and Roque, João and Leite, Valeriano and Nunes da Silva, Tiago},
title = {Somatostatin analogues and PRRT treatment for metastatic paraganglioma},
journal = {Endocrinology, Diabetes & Metabolism Case Reports},
year = {2026},
volume = {2026},
number = {4},
doi = {10.1530/edm-25-0150}
}
EUVIMED